FDA approves Atebrioz for fibrodysplasia ossificans progressiva
The FDA approval adds an oral ALK2 inhibitor for patients aged 12 years and older with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva.
Atebrioz (zilurgisertib) has been approved by the FDA to reduce the volume of new heterotopic ossification in adults and paediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva.
The approval, supported by the pivotal PROGRESS study, makes Atebrioz the third FDA-approved treatment for FOP and adds an oral therapy targeting the ALK2 pathway.
Field | Content |
Field | Content |
Alert Type | FDA Approval |
Company | Mirum Pharmaceuticals |
Product | Atebrioz (zilurgisertib) |
Indication | Fibrodysplasia ossificans progressiva (FOP) |
Patient Population | Adults and paediatric patients aged 12 years and older |
Technology/Modality | Oral ALK2 inhibitor |
Regulator | U.S. Food and Drug Administration |
Regulatory Status | FDA approved |
What Happened | FDA approved Atebrioz to reduce the volume of new heterotopic ossification in patients with FOP aged 12 years and older. |
Why It Matters | The approval adds a new oral treatment option for an ultra-rare genetic disorder characterised by progressive formation of bone in soft tissues. |
Supporting Evidence | The approval was supported by the pivotal PROGRESS study. |
Competitive Context | Atebrioz becomes the third FDA-approved treatment for FOP. |
Potential Impact | The therapy expands treatment options for eligible adolescents and adults living with FOP. |
Key Takeaway | Atebrioz provides a new FDA-approved oral ALK2-targeted treatment for FOP. |
What to Watch | US launch, clinical uptake and longer-term evidence on control of heterotopic ossification. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 25 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント